A method of inducing cardiomyocytes proliferation and treating heart diseases
The Agrin peptide induces cardiomyocyte proliferation by interacting with the Dystroglycan complex, addressing the limited regenerative capacity of adult cardiomyocytes and enhancing cardiac function through reduced scarring and improved immune modulation.
AU2023208156B2Pending Publication Date: 2026-07-09YEDA RES & DEV CO LTD
Patent Information
- Application Number
- AU2023208156
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-07-27
- Publication Date
- 2026-07-09
- Estimated Expiration
- 2036-10-27
AI Technical Summary
Technical Problem
The limited proliferative capacity of mammalian adult cardiomyocytes hinders effective cardiac regeneration following injuries such as myocardial infarction, leading to severe heart diseases due to the post-mitotic nature of these cells and the formation of rigid scars.
Method used
Utilizing an Agrin peptide that interacts with the Dystroglycan complex to induce cardiomyocyte proliferation, inhibiting sarcomerogenesis and promoting ERK activation, thereby enhancing cardiac regeneration.
Benefits of technology
The Agrin peptide increases cardiomyocyte proliferation, reduces scarring, and improves cardiac function by modulating the extracellular environment, facilitating robust cardiac regeneration and immune modulation.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000053_0000 
Figure 00000053_0001 
Figure 00000053_0002
Abstract
An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided. (GHMatters) P108838.AU.1 120085011 27 Jul 2023 2023208156
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
US20060216279A1